The U.S. Food and Drug Administration (FDA) has cleared medical imaging analysis software company RapidAI‘s 3D head and neck CT angiography (CTA) software, Lumina 3D.
Lumina 3D automates CTA reconstructions, speeding diagnosis and treatment processes, according to the firm. It is part of RapidAI’s Rapid Enterprise platform and allows neurointerventional specialists to visualize compressed images of the aortic arch, carotid tortuosity, and the entire neurovasculature on mobile devices, RapidAI said.